anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Over a period of 4 weeks, in addition to conventional physical therapy program, the participants will engage in WBVT on commercially available "ThinningPlate" vibration platform, 3 days per week for 15 minutes each session. Group 3 will be barefoot during WBVT.
The invention discloses a kind of liver targeting peptides and Angiostatin fusion and preparation method thereof and application. Does the present invention select plasmodium circumsporozoite protein in resisting CSP? the conservative I of N end district can with the acceptor of surface of hepatocytes---heparan sulfate proteoglycan HSPG? 19 amino acid (CSP of combination specifically? I-plus), utilize gene engineering method to be merged amino or the carboxyl terminal at Angiostatin, prepare liver targeting peptides and Angiostatin fusion. This fusion energy special target suppresses new vessels in liver and forms, and improves the local concentration of medicine at lesions position, reduces whole body consumption, reduces its toxic and side effect.
PCT No. PCT/JP95/00665 Sec. 371 Date Dec. 7, 1995 Sec. 102(e) Date Dec. 7, 1995 PCT Filed Apr. 6, 1995 PCT Pub. No. WO95/27470 PCT Pub. Date Oct. 19, 1995A tooth surface treating agent is provided which comprises a polymerization catalyst and an acidic compound, both water-soluble, the treating agent being capable of enhancing tooth adhesion. The tooth surface treating agent imparts strong adhesion to the enamel and dentin of teeth through simultaneous treatment thereof. The invention is mainly intended for use in the field of dentistry, but is also applicable as a treating agent for vital hard tissues in such fields as surgery, and orthopaedic or plastic surgery.
Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
The present invention provides computer-implemented systems and methods for ordering, performing, and reporting transgenic and targeted mutagenesis screening of genomic DNA. The methods are performed by a remote user's computer, a web site computer and a laboratory computer. The remote user, in communication with another computer, requests a screening of biological samples that are disposed in a multi-well plate. The remote user designates on his computer a variety of parameters necessary to perform the testing and identifies the location of samples in the multi-well plate. A computer at the laboratory receives this information and uses it to perform testing, and to prepare a sample test report that is returned to the remote user. A computer intermediate to the user's computer and the laboratory computer, such as a web site computer, may be used. The laboratory computer is configured to extract information from the remote user's electronic communication and transmit that information electronically to a supplier to order reagents necessary for the testing.
The purpose of this study is to determine if CBD has any effect on local inflammation in periodontal maintenance patients. This research is significant and innovative as it will act as a pivotal study to determine if CBD is worthy of further study in the area of periodontal disease and it will be a human clinical trial focusing on a specific aspect of periodontal disease, the maintenance patient. Many successful therapies exist for the active, untreated periodontal patient. Unfortunately, periodontology has not yet discovered a therapy that will predictably treat local inflammation in these patients which are at risk for further pocketing, bleeding on probing, bone loss and ultimately, tooth loss. Although CBD has been patented in various forms since the 1940s, its acceptance and availability to patients has only recently expanded exponentially. Marketing of CBD to periodontal patients as a means to control inflammation is already commonplace online and in CBD-specific shops; it is the duty of periodontology to determine the efficacy and success of this known anti-inflammatory compound as it relates to clinical periodontal parameters. To determine if CBD is a successful adjunct to conventional periodontal inflammation control therapies would be a boon to the advancement of oral health and to millions of patients that could benefit from this treatment.
PURPOSE:To obtain an antibody outside a living body, by cultivating a normal B cell in a culture medium containing interleukin 2 and a B cell differentiation factor. CONSTITUTION:A protoplasted B cell derived from a B cell sentitized with an antigen (which is regardless of the kind thereof and may be a single or plural antigens) is cultivated in a culture medium containing interleukin 2 and a B cell differentiation factor to give the aimed antibody with very high productivity. A human B cell increases the cell volume under antigenic stimulation. This means that the B cell transfers from the resting phase (G0 phase) to the G4d1 phase in the cell division cycle. The cell becomes a state in which in vivo action affecting the multiplication and differentiation of the B cell can be received thereafter. This is called a proplastic cell. The temperature at which the B cell is cultivated is preferably about 37 deg.C, and the aimed antibody can be sufficiently produced with very high productivity by cultivating the B cell preferably at 7.4pH for 3 days.
Currently the mechanisms of Complex Regional Pain Syndrome (CRPS) are poorly understood and stratification of either diagnosis or therapy is very weak. . There is a great need to develop and validate more objective methods to characterize and stratify CRPS that better diagnostic and therapeutic approaches are available. Spinal Cord Stimulation (SCS) has been used as the last resource to alleviate pain and re-establish function in CRPS patients. However, there is a disagreement over how it works. An underlying concept is that it works by modulating autonomic nervous system (ANS) activity. Therefore, ANS parameters could be useful to stratify patients. Our preliminary studies indicated that SCS has also an effect on blood pressure regulation and improves the CRPS patients' response to Valsalva maneuver -a test of autonomic function. The Autonomic Nervous System function in adult CRPS patients has not yet been studied. The only existing study of CRPS and autonomic function showed that 15% of the patients suffer from syncope and increased heart rate during upright position similar to same aged patients with postural tachycardia syndrome - a syndrome of autonomic dysfunction. It is unclear if autonomic dysfunction is present in CRPS patients because ANS activity is altered by chronic pain or whether or not ANS activity contributes to CRPS. Therefore, we proposed to study the autonomic function in CRPS patients by standardized autonomic function and to evaluate the effect of the SCS on autonomic function in CRPS patients before and after spinal cord stimulator implant. This is a 24 months study.
Embodiments of the present disclosure relate to methods, apparatuses, and computer-readable storage media for data processing. A method for data processing includes obtaining user data for a target user in a target environment, where the user data includes observations of a plurality of characteristics of the target user. The method further includes extracting at least a portion of the user data from the user data, wherein the at least a portion of the user data includes observed data of at least one of the plurality of features that affects the target feature and has causal invariance. The method also includes generating a prediction result for a target feature of the target user based at least in part on the user data according to a prediction model trained for the at least one feature. Embodiments of the present disclosure also provide an apparatus and a computer-readable storage medium capable of implementing the above method. Embodiments of the present disclosure are able to predict accurately and robustly based on features with causal invariance.
Recently, human umbilical cord mesenchymal stem cell (HucMSC) is a new focus of research in neurological diseases, and the beneficial effect of HucMSC is mediated by paracrine factors which are transported by exosome. Our previous study has shown that HucMSC-derived exosome could provide neuroprotection after traumatic brain injury (TBI). However, the underlying mechanisms were not fully understood. In the present study, we found that administration of exosome suppressed TBI-induced inflammation and ferroptosis. In addition, exosome activated the long non-coding ribonucleic acid (lncRNA) TUBB6/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway after TBI. However, exosome partly failed to provide neuroprotection following TBI when TUBB6 was knockdown. Importantly, exosome treatment also decreased neuron cell death, suppressed inflammation, inhibited ferroptosis and activated the lncRNA TUBB6/Nrf2 pathway after TBI in vitro. Taken together, our results provided the first evidence that HucMSC-derived exosome played a key role in neuroprotection after TBI through the lncRNA TUBB6/Nrf2 pathway.
The invention describes methods for proteomic analysis involving the mapping of samples in N-dimensional shape space. The applications include the classification of samples on the basis of the three-dimensional shapes of substances they contain. A panel of P (>>1) reagents, with P≧N, called X(j), with j=1 to P, is used, The binding strength of each of the X(j) reagents to each other is a P×P matrix. This matrix is used to define another set of P reagents called Y(j), with j=1 to P, each of which is a linear combination of the X(j) reagents and each of which is complementary to one of the X(j) reagents. N of the X(j) reagents together with the corresponding Y(j) reagents are used to define a shape space that has N approximately orthogonal axes. The definition of these axes facilitates classification of samples. Methods for measuring similarity between pairs of samples and between sets of samples in the context of the set of N reagent pairs X(j) and Y(j) with j=1 to N are described. Applications include classification of samples, quality control, methods of diagnosis, and formulation of vaccines.
Asthma is a chronic pulmonary disease with the worldwide prevalence. The structural alterations of airway walls, termed as "airway remodeling", are documented as the core contributor to the airway dysfunction during chronic asthma. Forkhead box transcription factor FOXK2 is a critical regulator of glycolysis, a metabolic reprogramming pathway linked to pulmonary fibrosis. However, the role of FOXK2 in asthma waits further explored. In this study, the chronic asthmatic mice were induced via ovalbumin (OVA) sensitization and repetitive OVA challenge. FOXK2 was upregulated in the lungs of OVA mice and downregulated after adenovirus-mediated FOXK2 silencing. The lung inflammation, peribronchial collagen deposition, and glycolysis in OVA mice were obviously attenuated after FOXK2 knockdown. Besides, the expressions of FOXK2 and SIRT2 in human bronchial epithelial cells (BEAS-2B) were increasingly upregulated upon TGF-β1 stimulation and downregulated after FOXK2 knockdown. Moreover, the functional loss of FOXK2 remarkably suppressed TGF-β1-induced epithelial-mesenchymal transition (EMT) and glycolysis in BEAS-2B cells, as manifested by the altered expressions of EMT markers and glycolysis enzymes. The glycolysis inhibitor 2-deoxy-d-glucose (2-DG) inhibited the EMT in TGF-β1-induced cells, making glycolysis a driver of EMT. The binding of FOXK2 to SIRT2 was validated, and SIRT2 overexpression blocked the FOXK2 knockdown-mediated inhibition of EMT and glycolysis in TGF-β1-treated cells, which suggests that FOXK2 regulates EMT and glycolysis in TGF-β1-treated cells in a SIRT2-dependnet manner. Collectively, this study highlights the protective effect of FOXK2 knockdown on airway remodeling during chronic asthma.
The present disclosure relates to spore surface display compositions comprising a spore having at least one nucleic acid sequence encoding for at least one polypeptide and operable to express the polypeptide on a surface of the spore. In some embodiments, the displayed polypeptide is displayed with a spore carrier protein. In some embodiments, the spore may be derived from a  Clostriduim  sp. such as  Clostriduim taeniosporum . Spore display compositions of the disclosure may include vaccines, fusion proteins, drug delivery devices, systems for generating an antibody to an antigen/peptide expressed on a spore surface, an anticancer drug, an immobilized enzyme system, a system for serological reagent preparation, a contaminant removal system, a biocatalysis system, a screening platform, a nanotechnology platform, a bioanalytical sensor, a molecular electronic system and/or a signal processing system. Methods for making and using these compositions are described.
Myfortic® is an enteric-coated formulation of the sodium salt derivative of mycophenolic acid (MPA) that is administered to control kidney graft rejection. Myfortic® was developed to improve MPA-related upper gastrointestinal (GI) side effects by delaying the release of MPA until it reaches the large surface of the small bowel. Approximately half of all the kidney transplant recipients in the United States have diabetes mellitus. A recent analysis of approximately 30,000 kidney transplant recipients included in the U.S. Renal Data System showed that 42% of patients had pre-transplant diabetes (1). Moreover, 15% to 20% of patients develop diabetes after transplantation, a condition that is commonly known as post-diabetes mellitus (1-3). It was previously shown that the rate and extent of MPA absorption is minimally affected by diabetes (4). Limited data is available in the current literature on Myfortic® and Simulect® based therapy in diabetic patients.
### Symptoms of Propoxyphene Overdosage

The manifestations of acute overdosage with propoxyphene are those of opioid overdosage. The patient is usually somnolent but may be stuporous or comatose and convulsing. Respiratory depression is characteristic. The ventilatory rate and/or tidal volume is decreased, which results in cyanosis and hypoxia. Pupils, initially pinpoint, may become dilated as hypoxia increases. Cheyne-Stokes respiration and apnea may occur. Blood pressure and heart rate are usually normal initially, but blood pressure falls and cardiac performance deteriorates, which ultimately results in pulmonary edema and circulatory collapse, unless the respiratory depression is corrected and adequate ventilation is restored promptly. Cardiac arrhythmias and conduction delay may be present. A combined respiratory-metabolic acidosis occurs owing to retained CO2 (hypercapnia) and to lactic acid formed during anaerobic glycolysis. Acidosis may be severe if large amounts of salicylates have also been ingested. Death may occur.

### Treatment of Propoxyphene Overdosage

Attention should be directed first to establishing a patent airway and to restoring ventilation. Mechanically assisted ventilation, with or without oxygen, may be required, and positive pressure respiration may be desirable if pulmonary edema is present. The opioid antagonist naloxone will markedly reduce the degree of respiratory depression, and should be administered promptly, preferably intravenously. The duration of action of the antagonist may be brief. If no response is observed after 10 mg of naloxone have been administered, the diagnosis of propoxyphene toxicity should be questioned.

In addition to the use of an opioid antagonist, the patient may require careful titration with an anticonvulsant to control convulsions. Activated charcoal can adsorb a significant amount of ingested propoxyphene. Dialysis is of little value in poisoning due to propoxyphene. Efforts should be made to determine whether other agents, such as alcohol, barbiturates, tranquilizers, or other CNS depressants, were also ingested, since these increase CNS depression as well as cause specific toxic effects or death.
PROBLEM TO BE SOLVED: To obtain a safe inhibitor of an amylase, containing a substance prepared by carrying out treatments of deoiling and extracting of Cinnamomi Cortex with a hydrous ethanol solution as an active ingredient, having excellent inhibiting actions on the amylase and hardly causing any bitterness or irritant smell peculiar to the Cinnamomi Cortex. SOLUTION: This inhibitor of an amylase contains a treated Cinnamomi Cortex prepared by carrying out treatments of deoiling and extracting of Cinnamomi Cortex with a hydrous ethanol solution as an active ingredient. For example, KANNAN Cinnamomi Cortex prepared from Cinnamomum cassia Blume as an original plant can be used as the Cinnamomi Cortex. Either of the treatments of deoiling and extracting with the hydrous ethanol solution can previously be performed; however, the deoiling can be carried out by the treatment with steam or a solvent. The extracting treatment with the hydrous ethanol solution is preferably performed by using an aqueous solution of ethanol at 50-90vol.% concentration in a weight of 1-5 times based on the Cinnamomi Cortex under heating conditions up to 80 deg.C for 1-5hr. The operations are preferably repeated 2-5 times.  When the objective inhibitor is used as a medicinal composition, the daily dose thereof for an adult is preferably 0.5-2,000mg, expressed in terms of the amount of active ingredient at a time and administered three times before a meal.
PURPOSE: A method for manufacturing a sustained release formulation of oral administration of capsule form is provided to improve bioavailability of drug. CONSTITUTION: A sustained release formulation for oral administration is a capsule form containing pharmacologically active ingredients, gas generating material, and floating polymers. The mixture of the pharmacologically active ingredients, gas generating material, and floating polymers is filled into a capsule in pellet form or powder form. The pharmacologically active ingredient is lipase inhibitor. The lipase inhibitor is lipstain, orlistat, cetilistat, panclicins, hesperidin, ebelactones, esterastin, or valilactone. The vapor generating material includes carbon dioxide generator and acid compound.
A self-closing antiseptic plaster (1) for puncturing blood vessels, muscle tissue, tissue, skin, organs (biopsy) or bone marrow is puncturable by cannulas, needles or the like. It has a backing layer (2), a sealing layer (5) made of a material having an elastic restoring force and a skin adhesive layer (3) applied to the underside U of the backing layer (2), the sealing layer being applied to the backing layer (2) by means of an adhesive layer (4). The backing layer (2) is usually thin. The backing layer (2), the sealing layer (5), the adhesive layer (4) and the skin adhesive layer (3) are transparent or approximately transparent in the entire area or at least in a superimposed partial area. The backing layer (2) and the sealing layer (5) are made of thin and soft materials so that any puncture site is visible and/or palpable through the self-closing antiseptic plaster (1). The advantages include the fact that the antiseptic state at the puncture site is preserved before, during and after the puncturing.
An applicator for transferring color-altering material from a substrate to hair or fibers, and methods for making and using the same. The applicator includes a color-altering dye material adhered to one surface of the substrate. The substrate is preferably flexible and thin, and made of a material such as a foil, a paper composition or a synthetic polymer. The substrate is further conformable to the shape of a human hand. The dye material is soluble in water and water-activated, and is carried by a portion of the substrate. Two processes for fabricating the applicators are disclosed. Each applicator carries a dye material which has a specific color. The applicators can be packaged singly, or together as a kit with the color of dye on the applicators being the same, different, or a combination thereof. Use of an applicator requires wetting the hairs or fibers, and then applying a substrate to the hairs or fibers. Next, the user wraps the substrate about the bundle of hair or fibers, and firmly squeezes and/or wipes the encircling substrate relative to the bundle of fibers or hair.
Graded drug challenges are the gold standard to exclude an immediate hypersensitivity reaction in patients with a low likelihood of drug allergy and are considered standard of care. Patients who tolerate a graded challenge are deemed to not be allergic to the drug and are not at increased risk for future reactions compared with the general population. Prior studies of graded challenges in appropriately selected patients have demonstrated low reaction rates with symptoms that were mainly mild and subjective in nature. The investigators are conducting a prospective study to determine the safety and outcomes of placebo-controlled graded drug challenges without prior skin testing in patients with a low-risk history of antibiotic hypersensitivity reaction based on history alone. Skin testing requires a separate visit and is, therefore, more time-consuming and costly than performing a graded challenge without skin testing. The investigators believe that they can determine if patients are at low-risk to react to an antibiotic based on a detailed history and, therefore, do not require skin testing prior to a challenge. Given the majority of symptoms to graded drug challenges reported in prior studies were mild and subjective, the investigators hypothesize that the rate of reaction to graded drug challenges without prior skin testing in patients with a low-risk history of drug hypersensitivity reaction based on history alone will not be meaningfully more than the rate of reaction to placebo. The investigators hypothesize that the rate of adverse reactions to drug challenges without prior skin testing will be not meaningfully more than the rate of adverse reactions with prior skin testing as was observed in the investigators' historical clinic cohort. All patients age 7 years or older with a history of a non-life-threatening reaction to an antibiotic are eligible to participate in a placebo-controlled graded drug challenge. The challenge is comprised of placebo followed by 30 minutes of observation, 1/10th of the treatment dose of the antibiotic the patient reported a reaction followed by 30 minutes of observation, and the full dose of the antibiotic followed by 1 hour of observation. All patients will be contacted via telephone within one month of a negative challenge to determine whether they experienced a delayed reaction. All patients will also be contacted via telephone within one year of a negative challenge to determine if they have safely taken the challenge drug.
Pevonedistat 25 mg/m\^2 in combination with docetaxel 75 mg/m\^2 or pevonedistat 20 mg/m\^2 in combination with carboplatin plus paclitaxel 175 mg/m\^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m\^2 or 20 mg/m\^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.